<DOC>
	<DOC>NCT01379534</DOC>
	<brief_summary>This is a prospective, multi-center, open-label, single-arm, non-randomized, Phase II study to evaluate the efficacy and safety of TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and/or metastatic endometrial cancer.</brief_summary>
	<brief_title>A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Patients with histologically confirmed diagnosis of advanced and/or metastatic endometrial cancer with available tissue specimen (either archival tissue or fixed fresh biopsy) Female patients ≥ 18 years old Documented radiologically confirmed progression of disease after prior firstline treatment evidence of progressive disease ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2 At least one measurable lesion as per RECIST Previous treatment with an FGFR inhibitor More than one line of treatment for advanced or metastatic disease Patients with uterine sarcomas, adenosarcoma, and malignant Mullerian tumors Patients with isolated recurrences (vaginal, pelvic, or paraaortic) potentially curative with radiation therapy or surgery Known central nervous system (CNS) metastases Malignancy within 3 years of study enrollment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Solid tumors,</keyword>
	<keyword>advanced endometrial cancer,</keyword>
	<keyword>Endometrial Cancer,</keyword>
	<keyword>Second-line treatment,</keyword>
	<keyword>VEGF,</keyword>
	<keyword>Neoplasms,</keyword>
	<keyword>Endometrial Neoplasms,</keyword>
	<keyword>Uterine Neoplasms,</keyword>
	<keyword>Female Genital Neoplasms,</keyword>
	<keyword>Cancer,</keyword>
	<keyword>Carcinoma,</keyword>
	<keyword>Uterine Diseases,</keyword>
	<keyword>Female Genital Diseases,</keyword>
	<keyword>Tumors,</keyword>
	<keyword>Oral Administration,</keyword>
	<keyword>Capsules,</keyword>
	<keyword>Tablets,</keyword>
	<keyword>CHIR258,</keyword>
	<keyword>CHIR-258,</keyword>
	<keyword>CHIR 258,</keyword>
	<keyword>TKI258,</keyword>
	<keyword>TKI-258,</keyword>
	<keyword>TKI 258</keyword>
</DOC>